Since the start of 2026, vaccine manufacturer Moderna (MRNA) has delivered a striking stock performance, with cumulative gains approaching ninety percent by late July and the share price at one point doubling from its level at the beginning of the year during intraday trading. This biotechnology company, known worldwide for its messenger RNA technology, is attempting to demonstrate to the market that it is not merely a fleeting phenomenon from the COVID-19 vaccine era. However, following this substantial rally in stock price, discussions have grown increasingly heated over whether its current valuation is justified and whether its growth momentum can be sustained.
The direct catalyst that drove Moderna’s stock sharply higher in mid-June was the positive advancement of its seasonal influenza vaccine, mRNA-1010. An advisory committee of the U.S. Food and Drug Administration (FDA) voted in favor of the vaccine’s benefit-risk profile. Nevertheless, this favorable news may have been overinterpreted by the market. Industry analysts point out that the seasonal influenza vaccine space is highly competitive, and even if mRNA-1010 achieves approximately one billion dollars in annual revenue by 2028, it would still be insufficient to fundamentally resolve the company’s current growth difficulties.
Looking across Moderna’s entire research pipeline, most projects are concentrated in areas such as influenza vaccines and respiratory syncytial virus (RSV) vaccines, and these products are unlikely to become disruptive performance engines in the short term. The sole exception is the personalized cancer vaccine mRNA-4157, developed in partnership with Merck, which is currently in multiple Phase 3 clinical trials and is viewed as the company’s most promising growth prospect. However, the development of cancer vaccines carries a high degree of uncertainty, and regulatory approval is far from guaranteed.
At the same time, the company’s financial pressures cannot be overlooked. As demand for COVID-19 vaccines continues to decline, Moderna has recorded an accumulated operating loss of 3.4 billion dollars over the past twelve months, and its dependence on COVID-19 vaccine sales remains fundamentally unchanged.
Although the stock has retreated from the eighty-five dollar high set earlier this month to below sixty dollars, Moderna’s market capitalization of over twenty billion dollars still appears expensive for a company that lacks clear and certain growth catalysts. Typically, high-risk biotechnology stocks trade at a valuation discount, but Moderna’s current trading price seems to already fully reflect expectations of future success, and investors may be underestimating the potential risks associated with pipeline setbacks or commercialization hurdles.
From a historical perspective, Moderna’s stock has been highly volatile. From early 2020 to early August 2021, the stock surged more than two thousand percent, but subsequently plummeted over eighty percent from its peak as demand for COVID-19 vaccines shrank and the company swung from profit to loss. This year’s strong rebound appears to reflect more the market’s preliminary recognition of the company’s strategic transformation rather than a fundamental improvement in its underlying business fundamentals.
In response to these challenges, Moderna is actively advancing cost restructuring and pipeline optimization. In its most recent earnings report, the company reaffirmed its goal of achieving up to ten percent revenue growth this year and disclosed that adjusted cash costs had decreased by twenty-six percent year over year. At present, the company has three approved products in the U.S. market (two COVID-19 vaccines and one RSV vaccine), and its influenza vaccine candidate mRNA-1010 is under regulatory review, with an approval decision expected no later than August 5. In addition, Moderna’s combined COVID-19/influenza vaccine has received approval in Europe, becoming the first such product globally and opening up new market opportunities for the company.
Management has focused the company’s medium- and long-term growth on three major areas: infectious disease vaccines, rare diseases, and oncology. Beyond the personalized cancer vaccine, patient enrollment has been completed for a therapy targeting propionic acidemia, with data expected to be released within the year, which could support subsequent regulatory filings.
